Marissa S. Pioso

Marissa S. Pioso

Auto-generated profile, based on publicly available information

Marissa S. Pioso

University of California, Los Angeles 2 Los Angeles, CA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Blood Cancer Discovery
Verified
Journal Article
Closed access
PDF file
EOElyse A Olesinski
Elyse A Olesinski
KBKaranpreet Singh Bhatia
Karanpreet Singh Bhatia
CWChuqi Wang
Chuqi Wang
MPMarissa S. Pioso
Marissa S. Pioso
XLXiao Xian Lin
Xiao Xian Lin
SBShrutiben Bhatt
Shrutiben Bhatt
In many cancers, mortality is associated with the emergence of relapse with multidrug resistance (MDR). Thus far, the investigation of cancer relapse mechanisms has largely focused on acquired genetic mutations. Using acute myeloid leukemia (AML) patient-derived xenografts (PDX), we systematically elucidated a basis of MDR and identified drug sensitivity in relapsed AML. We derived pharmacologic sensitivity for 22 AML PDX models using dynamic BH3 profiling (DBP), together with genomics and transcriptomics. Using in vivo acquired resistant PDXs, we found that resistance to unrelated, narrowly targeted agents in distinct PDXs was accompanied by broad resistance to drugs with disparate mechanisms. Moreover, baseline mitochondrial apoptotic priming was consistently reduced regardless of the class of drug-inducing selection. By applying DBP, we identified drugs showing effective in vivo activity in resistant models. This study implies evasion of apoptosis drives drug resistance and demonstrates the feasibility of the DBP approach to identify active drugs for patients with relapsed AML. Significance: Acquired resistance to targeted therapy remains challenging in AML. We found that reduction in mitochondrial priming and common transcriptomic signatures was a conserved mechanism of acquired resistance across different drug classes in vivo. Drugs active in vivo can be identified even in the multidrug resistant state by DBP.

1 May 2024
Verified
Other
Open access
PDF file
EOElyse A Olesinski
Elyse A Olesinski
KBKaranpreet Singh Bhatia
Karanpreet Singh Bhatia
CWChuqi Wang
Chuqi Wang
MPMarissa S. Pioso
Marissa S. Pioso
XLXiao Xian Lin
Xiao Xian Lin
SBShrutiben Bhatt
Shrutiben Bhatt
Supplemental Figure 11 shows comparison of leukemia-related genetic mutations in drug-resistant and parental AML PDX models.

1 May 2024
Verified
Other
Open access
PDF file
EOElyse A Olesinski
Elyse A Olesinski
KBKaranpreet Singh Bhatia
Karanpreet Singh Bhatia
CWChuqi Wang
Chuqi Wang
MPMarissa S. Pioso
Marissa S. Pioso
XLXiao Xian Lin
Xiao Xian Lin
SBShrutiben Bhatt
Shrutiben Bhatt
Supplemental Figure 10 shows immunoblotting of FLT-3 signaling pathway in quizartinib-resistant AML PDX models.

1 May 2024
Verified
Other
Open access
PDF file
EOElyse A Olesinski
Elyse A Olesinski
KBKaranpreet Singh Bhatia
Karanpreet Singh Bhatia
CWChuqi Wang
Chuqi Wang
MPMarissa S. Pioso
Marissa S. Pioso
XLXiao Xian Lin
Xiao Xian Lin
SBShrutiben Bhatt
Shrutiben Bhatt
Supplemental Figure 4 shows differential expression of BCL-2 family related genes and proteins in drug-resistant AML PDX models.

1 May 2024
Verified
Other
Open access
PDF file
EOElyse A Olesinski
Elyse A Olesinski
KBKaranpreet Singh Bhatia
Karanpreet Singh Bhatia
CWChuqi Wang
Chuqi Wang
MPMarissa S. Pioso
Marissa S. Pioso
XLXiao Xian Lin
Xiao Xian Lin
SBShrutiben Bhatt
Shrutiben Bhatt
Supplemental Figure 2 shows RNA-seq signature of drug-resistant AML PDX models.

1 May 2024
Verified
Other
Open access
PDF file
EOElyse A Olesinski
Elyse A Olesinski
KBKaranpreet Singh Bhatia
Karanpreet Singh Bhatia
CWChuqi Wang
Chuqi Wang
MPMarissa S. Pioso
Marissa S. Pioso
XLXiao Xian Lin
Xiao Xian Lin
SBShrutiben Bhatt
Shrutiben Bhatt
Supplemental Figure 10 shows immunoblotting of FLT-3 signaling pathway in quizartinib-resistant AML PDX models.